A study of 43 patients treated with 6 months of oxaliplatin for colorectal cancer found that serum NfL (sNfL) levels were higher in patients with National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade 3 peripheral neuropathy compared with Grades 0–2 after 6 months.8 This evidence concerns the gene NEFL and peripheral neuropathy.